PMC4721054_01
CT showing the primary tumor (a; arrow) and a swollen lymph node (b; arrowhead)
12957_2016_773_Fig1_HTML.jpg
PMC4721054_01_12957_2016_773_Fig1_HTML.jpg
Fig1
Contrast-enhanced computed tomography (CT) showed a 45-mm low-attenuating tumor in the head of the pancreas, causing dilatation of the pancreatic duct and common bile duct (Fig. 1a). CT further revealed a 24-mm lymph node along the common hepatic artery (Fig. 1b).
CT images after chemoradiation therapy (a, b)
12957_2016_773_Fig2_HTML.jpg
PMC4721054_01_12957_2016_773_Fig2_HTML.jpg
Fig2
The tumor shrunk to a diameter of 18 mm, and the contour between the SMV and the tumor became clear (Fig. 2).
Adenopathy of a left accessory nerve lymph node (a; arrow) and middle deep cervical lymph nodes (b; arrowhead)
12957_2016_773_Fig3_HTML.jpg
PMC4721054_01_12957_2016_773_Fig3_HTML.jpg
Fig3
Further, positron-emission tomography (PET)-CT revealed an abnormal accumulation at these lymph nodes (Fig. 3).
CT after chemoradiation therapy showing complete response to the treatment (a, b)
12957_2016_773_Fig4_HTML.jpg
PMC4721054_01_12957_2016_773_Fig4_HTML.jpg
Fig4
The lymphadenopathy became unremarkable on a CT scan obtained 17 months postoperatively (Fig. 4), and the DUPAN-2 level decreased to normal.